keyword
MENU ▼
Read by QxMD icon Read
search

Vedolizumab

keyword
https://www.readbyqxmd.com/read/29205421/systematic-review-with-network-meta-analysis-comparative-assessment-of-tofacitinib-and-biological-therapies-for-moderate-to-severe-ulcerative-colitis
#1
S Bonovas, T Lytras, G Nikolopoulos, L Peyrin-Biroulet, S Danese
BACKGROUND: Biological therapies have improved the care of patients with ulcerative colitis (UC). Tofacitinib, an oral small-molecule Janus kinase inhibitor, is potentially a new treatment option. AIM: To comparatively assess efficacy and harm of tofacitinib and biologics (infliximab, adalimumab, golimumab and vedolizumab) in adult patients not previously exposed to TNF antagonists. METHODS: We performed a comprehensive search of PubMed, Embase, Scopus, clinical trial registries, regulatory authorities' websites and major conference proceedings, through August 2017, to identify randomised, placebo-controlled or head-to-head trials assessing tofacitinib or biologics as induction and/or maintenance therapy in moderate-to-severe UC...
December 4, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29205406/systematic-review-and-network-meta-analysis-first-and-second-line-pharmacotherapy-for-moderate-severe-ulcerative-colitis
#2
S Singh, M Fumery, W J Sandborn, M H Murad
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe ulcerative colitis (UC). AIM: To assess comparative efficacy and safety of different therapies as first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor(TNF)-α) agents for moderate-severe UC, through a systematic review and network meta-analysis, and appraise quality of evidence (QoE) using grading of recommendations, assessment, development and evaluation (GRADE) approach...
December 4, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29196458/integrin-%C3%AE-4%C3%AE-7-blockade-preferentially-impacts-ccr6-lymphocyte-subsets-in-blood-and-mucosal-tissues-of-naive-rhesus-macaques
#3
Giulia Calenda, Rassamon Keawvichit, Géraldine Arrode-Brusés, Kovit Pattanapanyasat, Ines Frank, Siddappa N Byrareddy, James Arthos, Claudia Cicala, Brooke Grasperge, James L Blanchard, Agegnehu Gettie, Keith A Reimann, Aftab A Ansari, Elena Martinelli
Infusion of a simianized anti-α4β7 mAb (Rh-α4β7) just before and following SIV infection protected rhesus macaques from developing AIDS and partially from vaginal SIV acquisition. Recently, short-term treatment with Rh-α4β7 in combination with cART was found to lead to prolonged viral suppression after withdrawal of all therapeutic interventions. The humanized form of Rh-α4β7, vedolizumab, is a highly effective treatment for inflammatory bowel disease. To clarify the mechanism of action of Rh-α4β7, naive macaques were infused with Rh-α4β7 and sampled in blood and tissues before and after treatment to monitor several immune cell subsets...
December 1, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29192530/cost-effectiveness-analysis-of-infliximab-adalimumab-golimumab-and-vedolizumab-for-moderate-to-severe-ulcerative-colitis-in-spain
#4
Cristina Trigo-Vicente, Vicente Gimeno-Ballester, Raquel Montoiro-Allué, Alejandro López-Del Val
OBJECTIVES: Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS: A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National Health Service with an over 10 years of time horizon, with a discount rate of 3%, and established threshold of €30,000/quality-adjusted life-year (QALY)...
December 1, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29192397/ustekinumab-for-treating-moderately-to-severely-active-crohn-s-disease-after-prior-therapy-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#5
Robert Hodgson, Matthew Walton, Mousumi Biswas, Teumzghi Mebrahtu, Nerys Woolacott
As part of the single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited Janssen to submit evidence on the clinical and cost effectiveness of their drug ustekinumab, an interleukin-12/23 inhibitor, for treating moderate-to-severe active Crohn's disease (CD). The Centre for Reviews and Dissemination (CRD) and Centre for Health Economics (CHE) Technology Appraisal Group at the University of York was commissioned to act as the independent Evidence Review Group (ERG)...
November 30, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29189313/vedolizumab-associated-acute-respiratory-distress-syndrome
#6
Sudheer Nambiar, Asha Karippot, Tony Oliver
No abstract text is available yet for this article.
November 7, 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29182760/expression-patterns-of-tnf%C3%AE-madcam1-and-stat3-in-intestinal-and-skin-manifestations-of-inflammatory-bowel-disease
#7
Stephan R Vavricka, Jose A Galván, Heather Dawson, Alex Soltermann, Luc Biedermann, Michael Scharl, Alain M Schoepfer, Gerhard Rogler, Mareike B Prinz Vavricka, Luigi Terracciano, Alexander Navarini, Inti Zlobec, Alessandro Lugli, Thomas Greuter
Background: Pathogenesis of cutaneous extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) remains elusive. Efficacy of anti-TNF agents suggests TNF-dependent mechanisms. The role of other biologics such as anti-integrins or JAK-inhibitors is not yet clear. Methods: We performed immunohistochemistry for TNFα, NFκB, STAT1/STAT3, MAdCAM1, CD20/68, caspase 3/9, IFNγ, Hsp-27/70 on 240 intestinal (55 controls, 185 IBD) and 64 skin biopsies (11 controls, 18 Erythema nodosum (EN), 13 Pyoderma gangenosum (PG), 22 psoriasis)...
November 22, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29162338/interstitial-nephritis-secondary-to-vedolizumab-treatment-in-crohn-disease-and-safe-rechallenge-using-steroids-a-case-report
#8
Elodie Bailly, Florent Von Tokarski, Frédérique Beau-Salinas, Laurence Picon, Elodie Miquelestorena-Standley, Geoffroy Rousseau, Annie-Pierre Jonville-Bera, Jean-Michel Halimi
Vedolizumab is a gut-selective humanized monoclonal antibody that binds selectively to the α4 β7 integrin and acts as a lymphocyte-homing antagonist. It is indicated in ulcerative colitis and Crohn disease. We report a case of acute interstitial nephritis following vedolizumab infusion in a 55-year-old white woman treated for severe Crohn disease resistant to several therapies. Other kidney disease causes were ruled out. Glucocorticoids were administrated, leading to full renal recovery. In the absence of other therapeutic options, vedolizumab was re-administered along with transient corticosteroids; this treatment was well tolerated...
November 18, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/29140943/antibodies-toward-vedolizumab-appear-from-the-first-infusion-onward-and-disappear-over-time
#9
Sumin Bian, Erwin Dreesen, Ho Tsun Tang, Griet Compernolle, Miet Peeters, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
BACKGROUND: Vedolizumab (VDZ) has been approved for the treatment of patients with moderate-to-severe Crohn's disease and ulcerative colitis. The GEMINI trials reported a low prevalence of anti-VDZ antibodies (AVA). However, the AVA assays used in GEMINI were drug sensitive, resulting in a possible underestimation of the rate of AVA formation. This study aimed to monitor immunogenicity of VDZ in a real-life cohort using a drug-resistant AVA assay. METHODS: Using a combination of VDZ/AVA complex precipitation and acid dissociation, a drug-resistant assay for AVA detection in the presence of high VDZ concentrations has been developed and analytically validated...
December 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29139091/pharmacological-approach-to-the-management-of-crohn-s-disease-patients-with-perianal-disease
#10
REVIEW
Fernando Bermejo, Iván Guerra, Alicia Algaba, Antonio López-Sanromán
Perianal localization of Crohn's disease involves significant morbidity, affects quality of life and results in an increased use of healthcare resources. Medical and surgical therapies contribute to its management. The objective of this review is to address the current understanding in the management of perianal Crohn's disease, with the main focus in reviewing pharmacological therapies, including stem cells. In complex fistulas, once local sepsis has been controlled by surgical drainage and/or antibiotics, anti-TNF drugs (infliximab, adalimumab) are the first-line therapy, with or without associated immunomodulators...
November 14, 2017: Drugs
https://www.readbyqxmd.com/read/29115855/an-indirect-comparison-of-ustekinumab-and-vedolizumab-in-the-therapy-of-tnf-failure-crohn-s-disease-patients
#11
Paweł Kawalec, Paweł Moćko
AIM: An indirect comparison of ustekinumab versus vedolizumab in patients with active moderate-to-severe Crohn's disease who were nonresponsive or intolerant to previous TNF-antagonist therapy. METHODS: A systematic review was performed in Medline via PubMed, Embase, Cochrane Library, until 30 April 2017. Inclusion criteria were: randomized controlled trials, patients treated for Crohn's disease, ustekinumab or vedolizumab therapy. Included trials were critically appraised and afterward indirect comparison by Bucher was conducted; the manuscript was prepared in accordance to the PRISMA requirements...
November 8, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29111083/postoperative-outcomes-in-vedolizumab-treated-pediatric-patients-undergoing-abdominal-operations-for-inflammatory-bowel-disease
#12
Amy L Lightner, Chung Sang Tse, D Dean Potter, Christopher Moir
INTRODUCTION: Recent studies have found vedolizumab to be an independent predictor of increased rates of postoperative complications and surgical site infections (SSIs) in adults with inflammatory bowel disease (IBD), but studies in the pediatric surgical population are lacking. We sought to determine the 30-day postoperative infectious complication rate among pediatric IBD patients who received vedolizumab within 12weeks of a major abdominal operation. METHODS: A retrospective chart review was performed on pediatric IBD patients who underwent an abdominal operation between 5/20/2014 and 6/1/2017...
October 9, 2017: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/29106505/successful-treatment-with-vedolizumab-in-a-patient-with-chronic-refractory-pouchitis-and-primary-sclerosing-cholangitis
#13
M Coletta, M Paroni, F Caprioli
No abstract text is available yet for this article.
July 5, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29081667/cost-effectiveness-of-vedolizumab-compared-with-conventional-therapy-for-ulcerative-colitis-patients-in-the-uk
#14
Michele R Wilson, Ismail Azzabi Zouraq, Helene Chevrou-Severac, Ross Selby, Matthew C Kerrigan
OBJECTIVE: To examine the clinical and economic impact of vedolizumab compared with conventional therapy in the treatment of moderately-to-severely active ulcerative colitis (UC) in the UK based on results of the GEMINI I trial. METHODS: A decision-analytic model in Microsoft Excel was used to compare vedolizumab with conventional therapy (aminosalicylates, corticosteroids, immunomodulators) for the treatment of patients with UC in the UK. We considered the following three populations: the overall intent-to-treat population from the GEMINI I trial, patients naïve to anti-TNF therapy, and those who had failed anti-TNF-therapy...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29077833/vedolizumab-in-ibd-lessons-from-real-world-experience-a-systematic-review-and-pooled-analysis
#15
Tal Engel, Bella Ungar, Diana E Yung, Shomron Ben-Horin, Rami Eliakim, Uri Kopylov
Background: Vedolizumab (VDZ) is an anti-integrin monoclonal antibody effective in ulcerative colitis (UC) and Crohn's disease (CD). Several real-world experience (RWE) studies with VDZ were published to date. The aim of this systematic review was to summarize the available real-life experience with VDZ. Methods: We performed a systematic review of the available RWE studies of VDZ in CD and UC. We performed a pooled analysis of the available efficacy and safety data for induction and maintenance treatment in adult cohorts...
October 25, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28981886/perioperative-use-of-vedolizumab-is-not-associated-with-postoperative-infectious-complications-in-patients-with-ulcerative-colitis-undergoing-colectomy
#16
Marc Ferrante, Anthony de Buck van Overstraeten, Nikkie Schils, Annick Moens, Gert Van Assche, Albert Wolthuis, Séverine Vermeire, André D'Hoore
Background and Aims: Preoperative use of vedolizumab has been associated with increased short-term postoperative infectious complications. We assessed this risk in a single-centre cohort of patients with ulcerative colitis undergoing colectomy. Methods: Chart review was performed for all colectomies between 2006 and 2016. Short-term postoperative [non]infectious complications were evaluated within 30 days after colectomy. The comprehensive complication index was calculated based on all reported events...
October 27, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28978958/vedolizumab-in-patients-with-common-variable-immune-deficiency-and-gut-inflammation
#17
Brigid S Boland, Marc A Riedl, Mark A Valasek, Sheila E Crowe, William J Sandborn
No abstract text is available yet for this article.
October 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28978957/long-term-combination-therapy-with-anti-tnf-plus-vedolizumab-induces-and-maintains-remission-in-therapy-refractory-ulcerative-colitis
#18
Sarah Fischer, Timo Rath, Carol-Immanuel Geppert, Bernhard Manger, Georg Schett, Markus F Neurath, Raja Atreya
No abstract text is available yet for this article.
October 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28974896/access-to-biologicals-in-crohn-s-disease-in-ten-european-countries
#19
Márta Péntek, Peter L Lakatos, Talitha Oorsprong, László Gulácsi, Milena Pavlova, Wim Groot, Fanni Rencz, Valentin Brodszky, Petra Baji, Crohn's Disease Research Group
AIM: To analyze access (availability, affordability and acceptability) to biologicals for Crohn's disease (CD) in ten European countries and to explore the associations between these dimensions, the uptake of biologicals and economic development. METHODS: A questionnaire-based survey combined with desk research was carried out in May 2016. Gastroenterologists from the Czech Republic, France, Germany, Hungary, Latvia, Poland, Romania, Slovakia, Spain and Sweden were invited to participate and provide data on the availability of biologicals/biosimilars, reimbursement criteria, clinical practice and prices, and use of biologicals...
September 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28973005/a-systematic-review-of-cost-effectiveness-studies-comparing-conventional-biological-and-surgical-interventions-for-inflammatory-bowel-disease
#20
REVIEW
Nadia Pillai, Mark Dusheiko, Bernard Burnand, Valérie Pittet
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic disease placing a large health and economic burden on health systems worldwide. The treatment landscape is complex with multiple strategies to induce and maintain remission while avoiding long-term complications. The extent to which rising treatment costs, due to expensive biologic agents, are offset by improved outcomes and fewer hospitalisations and surgeries needs to be evaluated. This systematic review aimed to assess the cost-effectiveness of treatment strategies for IBD...
2017: PloS One
keyword
keyword
1883
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"